Turashvili, Gulisa; Bouchal, Jan; Ehrmann, Jiri; Fridman, Eduard; Skarda, Jozef; Kolara, Zdenek
June 2007
Biomedical Papers of the Medical Faculty of Palacky University i;2007, Vol. 151 Issue 1, p59
Academic Journal
Aims. Invasive ductal and lobular carcinomas are the most common histological types of breast cancer. The loss of E-cadherin expression has been suggested to be the most reliable marker for invasive lobular carcinoma. The aim of our study was to identify the diagnostic usefulness of novel markers in the diff erentiation of these tumor types. Methods. We examined tissue microarrays (TMA) which were constructed from surgical specimens of 119 breast cancer patients. TMA consisted of 80 ductal carcinomas, 29 lobular carcinomas and special type cancers. TMA sections were stained using standard immunohistochemical methods. Monoclonal mouse antibodies against E-cadherin, cytokeratin 5/6 and 17, and polyclonal mouse antibodies against EMP1, DDR1, PRKCI and DVL1 were used. Results. E-cadherin was absent in 93.3 % of lobular tumors compared with only 15 % of ductal tumors (p < 0.0001). EMP1 and DVL1 were overexpressed in lobular tumors (93.1 % and 96.5 %, respectively), whereas PRKCI and DDR1 were positive in ductal cancers (90 % and 96.2 %, respectively). Reduced expression or absence of both cytokeratins 5/6 and 17 was found in both tumor tissues in comparison to normal terminal duct lobular units (p < 0.0001). Conclusions. Apart from the well-established marker, E-cadherin, proteins examined on TMA slides by immunohistochemistry (EMP1, DVL1, DDR1, PRKCI) may represent novel tissue markers helpful in the diff erentiation of ductal and lobular breast cancers. Further studies with larger sets of patients are desirable, to verify the complete immunohistochemical profi les of various histological types of breast cancer and determine the prognostic and predictive significance of novel markers.


Related Articles

  • TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. Levin Jørgensen, Charlotte; Bjerre, Christina; Ejlertsen, Bent; Bjerre, Karsten D.; Balslev, Eva; Bartels, Annette; Brünner, Nils; Nielsen, Dorte L. // BMC Cancer;2014, Vol. 14 Issue 1, p499 

    Background Tissue inhibitor of metalloproteinases-1 (TIMP-1) has anti-apoptotic functions, which may protect TIMP-1 positive cancer cells from the effects of chemotherapy such as docetaxel and gemcitabine. The purpose of the present study was to evaluate TIMP-1 immunoreactivity as a prognostic...

  • Presence of CHD1L Over-Expression Is Associated with Aggressive Tumor Biology and Is a Novel Prognostic Biomarker for Patient Survival in Human Breast Cancer. Wu, Jiayi; Zong, Yu; Fei, Xiaochun; Chen, Xiaosong; Huang, Ou; He, Jianrong; Chen, Weiguo; Li, Yafen; Shen, Kunwei; Zhu, Li // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Background: The chromodomain helicase/adenosine triphosphatase DNA binding protein 1–like gene (CHD1L) is a recently identified oncogene localized at 1q21. CHD1L protein over-expression in primary hepatocellular carcinoma is correlated with enhanced apoptosis inhibition, reduced...

  • Heparanase Expression in Circulating Lymphocytes of Breast Cancer Patients Depends on the Presence of the Primary Tumor and/or Systemic Metastasis. Rachell Theodoro, Thérèse; de Matos, Leandro Luongo; Sant Anna, Aleksandra Vanessa Lambiasi; Fonseca, Fernando Luiz Affonso; Semedo, Patrícia; Martins, Lourdes Conceição; Nader, Helena Bonciani; Del Giglio, Auro; Da Silva Pinhal, Maria Aparecida // Neoplasia;Jun2007, Vol. 9 Issue 6, p504 

    Heparanase is an endo-β-glucuronidase that is capable of degrading heparan sulfate chains of proteoglycans, generating a variety of bioactive molecules such as growth factors and chemotactic and angiogenic agents. The expression of heparanase was investigated in the peripheral blood...

  • Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Buffaz, Pierre-Denis; Gauchez, Anne-Sophie; Caravel, Jean-Pierre; Vuillez, Jean-Philippe; Cura, Christophe; Agnius-Delord, Claudine; Fagret, Daniel // European Journal of Nuclear Medicine;1999, Vol. 26 Issue 1, p8 

    Abstract. Considering the current need to improve cost-effectiveness in cancer patient management, a prospective study was undertaken in order to define the optimal combination of bone scan and tumour marker assays in breast and lung cancer strategies, as has been done in the case of prostate...

  • Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients. Domschke, Christoph; Schuetz, Florian; Sommerfeldt, Nora; Rom, Joachim; Scharf, Alexander; Sohn, Christof; Schneeweiss, Andreas; Beckhove, Philipp // Cancer Immunology, Immunotherapy;Mar2010, Vol. 59 Issue 3, p479 

    Tumor-specific memory T cells are detectable in the bone marrow (BM) of a majority of breast cancer patients. In vitro they can be reactivated to IFN-γ producing, cytotoxic effector cells and reject autologous, xenotransplanted tumors in NOD/SCID mice after specific restimulation with...

  • SERUM FERRITIN IN HEALTHY WOMEN AND BREAST CANCER PATIENTS. ćujić, Danica; Stefanoska, Ivana; Golubović, Snežana // Journal of Medical Biochemistry;Mar2011, Vol. 30 Issue 1, p33 

    Serum tumor markers are important tools in managing patients with breast cancer. Currently used CA 15-3 and CEA have found their clinical application particularly in the follow-up of patients with advanced disease. Ferritin belongs to a group of other molecules of potential interest to...

  • Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Burges, Alexander; Brüning, Ansgar; Dannenmann, Christine; Blankenstein, Thomas; Jeschke, Udo; Shabani, Naim; Friese, Klaus; Mylonas, Ioannis // Archives of Gynecology & Obstetrics;May2010, Vol. 281 Issue 3, p511 

    Ovarian cancer is a gynecologic cancer with a high mortality rate. This shows the need of effective screening methods and reliable cancer markers for ovarian cancer staging and appropriate effective cancer treatment. Expression of estrogen receptor α and β was studied by immunhistochemical...

  • Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain. Koizumi, Mitsuru; Yoshimoto, Masataka; Kasumi, Fujio; Iwase, Takuji; Ogata, Etsuro // BMC Cancer;2010, Vol. 10, p423 

    Background: Skeletal metastases are often accompanied by bone pain. To investigate the clinical meaning of bone pain associated with skeletal metastasis in breast cancer patients after surgery, we explored whether the presence of bone pain was due to skeletal-related events (SREs) or survival...

  • Mammaglobin Expression in Lymph Nodes Is an Important Marker of Metastatic Breast Carcinoma. Jae-Ho Han, María Victoria; Yup Kang; Ha-Chul Shin, María Victoria; Hyun-Soo Kim; Young-Mo Kang, María Victoria; Young-Bae Kim; Seung-Yeon Oh, María Victoria // Archives of Pathology & Laboratory Medicine;Oct2003, Vol. 127 Issue 10, p1330 

    Context.--Organ specificity is a desirable property of a tumor marker, especially in metastatic adenocarcinomas of unknown primary origin. Mammaglobin, a mammary-specific member of the uteroglobin family, is known to be overexpressed in human breast cancer. Objective.--We investigated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics